<DOC>
	<DOC>NCT01734824</DOC>
	<brief_summary>The etiology of bone marrow edema (BME) is still uncertain. Several studies report therapeutic success with antiresorptive drugs. This study investigates antiresorptive and osteoanabolic drugs versus placebo in BME</brief_summary>
	<brief_title>Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo</brief_title>
	<detailed_description>Patients are assigned to receive either denosumab 60mg sc (once) or placebo or daily teriparatide sc for three months or placebo. MRI examinations at baseline and after three months will be performed. Serum bone turnover markers will be evaluated as well as QoL questionnaires.</detailed_description>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>MRI diagnosed bone marrow edema any prior antiresorptive or osteoanabolic treatment any prior therapy with strontium ranelate Hyper/hypocalcemia malignancies pregnancy and contraindication against denosumab or teriparatide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>bone marrow edema, denosumab, PTH 1-84</keyword>
</DOC>